OLMA Quote, Financials, Valuation and Earnings

Cogent Biosciences, Inc. has a net margin of -- compared to Olema Pharmaceuticals, Inc.'s net margin of --. Olema Pharmaceuticals, Inc.'s return on equity of -45.61% beat Cogent Biosciences, Inc.'s return on equity of -117.99%.

Olema Pharmaceuticals, Inc. has a consensus price target of $45.30, signalling upside risk potential of 77.16%. On the other hand Cogent Biosciences, Inc. has an analysts' consensus of $50.25 which suggests that it could grow by 42.15%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Cogent Biosciences, Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Cogent Biosciences, Inc..

Olema Pharmaceuticals, Inc. has a beta of 1.919, which suggesting that the stock is 91.942% more volatile than S&P 500. In comparison Cogent Biosciences, Inc. has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.585%.

Olema Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cogent Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Cogent Biosciences, Inc. pays out -- of its earnings as a dividend.

Olema Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Cogent Biosciences, Inc. quarterly revenues of --. Olema Pharmaceuticals, Inc.'s net income of -$42.2M is higher than Cogent Biosciences, Inc.'s net income of -$80.9M. Notably, Olema Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Cogent Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals, Inc. is -- versus 55.99x for Cogent Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Genprex, Inc. has a net margin of -- compared to Olema Pharmaceuticals, Inc.'s net margin of --. Olema Pharmaceuticals, Inc.'s return on equity of -45.61% beat Genprex, Inc.'s return on equity of -900.4%.

Olema Pharmaceuticals, Inc. has a consensus price target of $45.30, signalling upside risk potential of 77.16%. On the other hand Genprex, Inc. has an analysts' consensus of $7.50 which suggests that it could grow by 16945.46%. Given that Genprex, Inc. has higher upside potential than Olema Pharmaceuticals, Inc., analysts believe Genprex, Inc. is more attractive than Olema Pharmaceuticals, Inc..

Olema Pharmaceuticals, Inc. has a beta of 1.919, which suggesting that the stock is 91.942% more volatile than S&P 500. In comparison Genprex, Inc. has a beta of -0.810, suggesting its less volatile than the S&P 500 by 180.953%.

Olema Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genprex, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Genprex, Inc. pays out -- of its earnings as a dividend.

Olema Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Genprex, Inc. quarterly revenues of --. Olema Pharmaceuticals, Inc.'s net income of -$42.2M is lower than Genprex, Inc.'s net income of -$3.8M. Notably, Olema Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Genprex, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals, Inc. is -- versus -- for Genprex, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to Olema Pharmaceuticals, Inc.'s net margin of 21.32%. Olema Pharmaceuticals, Inc.'s return on equity of -45.61% beat Pfizer Inc.'s return on equity of 10.84%.

Olema Pharmaceuticals, Inc. has a consensus price target of $45.30, signalling upside risk potential of 77.16%. On the other hand Pfizer Inc. has an analysts' consensus of $28.66 which suggests that it could grow by 12.47%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Pfizer Inc..

Olema Pharmaceuticals, Inc. has a beta of 1.919, which suggesting that the stock is 91.942% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

Olema Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.75% to investors and pays a quarterly dividend of $0.43 per share. Olema Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Olema Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Olema Pharmaceuticals, Inc.'s net income of -$42.2M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Olema Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals, Inc. is -- versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Replimune Group, Inc. has a net margin of -- compared to Olema Pharmaceuticals, Inc.'s net margin of --. Olema Pharmaceuticals, Inc.'s return on equity of -45.61% beat Replimune Group, Inc.'s return on equity of -82.53%.

Olema Pharmaceuticals, Inc. has a consensus price target of $45.30, signalling upside risk potential of 77.16%. On the other hand Replimune Group, Inc. has an analysts' consensus of $12.57 which suggests that it could grow by 56.56%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Replimune Group, Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Replimune Group, Inc..

Olema Pharmaceuticals, Inc. has a beta of 1.919, which suggesting that the stock is 91.942% more volatile than S&P 500. In comparison Replimune Group, Inc. has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.585%.

Olema Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Replimune Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Replimune Group, Inc. pays out -- of its earnings as a dividend.

Olema Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Replimune Group, Inc. quarterly revenues of --. Olema Pharmaceuticals, Inc.'s net income of -$42.2M is higher than Replimune Group, Inc.'s net income of -$83.1M. Notably, Olema Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Replimune Group, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals, Inc. is -- versus -- for Replimune Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.